Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Screening tests are critical in early detection because they can find cancer before symptoms appear, when treatment is more ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...

Anagnostou, MD, MSc, PhD, FACAAI, did not realize she was already on her way to becoming an allergist when working a ...

Scientists discover how to rouse the immune system around "cold" tumors, making them vulnerable to cancer-killing immune ...

Incubators, 250+ Top Startups, 20+ Venture Capitalists, 40 Leading Corporations, Policy Makers Participate in Chandigarh ...